Rate Video

ASH 2014 | Recent investigational advances in the management of relapsed/refractory myeloma

Paul Richardson • 6 Dec 2014

ASH 2014

Multiple Myeloma Antibodies Carfilzomib Daratumumab Elotuzumab Panobinostat Pomalidomide Ricolinostat

Prof Paul Richardson (Dana-Farber Cancer Institute, Boston, MA) summarises of results of clinical trials in the management of relapsed or refractory multiple myeloma presented at the 2014 American Society of Hematology (ASH) Annual Meeting.

Investigational agents discussed include: proteasome inhibitor, carfilzomib; anti-CD38 monoclonal antibody, daratumumab: anti-SLAMF7 monoclonal antibody, elotuzumab; histone deacetylase (HDAC) inhibitor, panobinostat; HDAC6 inhibitor, ricolinostat; immunomodulatory agent, pomalidomide.

Selinexor: an underappreciated MM development

Paul Richardson • 3 Jun 2019

Overview of the Tourmaline-MM1 study in relapsed/refractory multiple myeloma

Paul Richardson • 4 Dec 2015

The promise of belantamab mafodotin for the treatment of multiple myeloma

Paul Richardson • 14 May 2022

Endothelial dysfunction in transplant: defibrotide for VOD

Paul Richardson • 18 Mar 2018

Related Videos

A.R.R.O.W. study: carfilzomib dosing in frail MM patients

Maria-Victoria Mateos

Managing CRS in myeloma

Managing transplant patients during the COVID-19 pandemic

Christian Chabannon

DNA methyltransferase inhibitors: daratumumab enhancement for MM